Tuesday, July 16, 2013

Biosensors International : Competitor’s DES approved in Japan (DB)

Biosensors International :
Price at 10 Jul 2013 (SGD) 1.06
Price target - 12mth (SGD) 1.15
52-week range (SGD) 1.40 - 1.02
Competitor’s DES approved in Japan

Royalty revenue is likely to decline further in 2013
We anticipate further market share decline in Japan for Nobori with competitors’ launch of new products, such as Xience Xpedition. We estimate royalty rate at 32-34% for Japan sales of Nobori, where Biosensors does not have a guarantee for minimal royalty payment. Since achieving 30% market share after product launch in May 2011, Nobori market share has declined to 16%-17% as of 1Q13 by our estimate. We model 10% sales decline in Japan for FY14.


What’s New? Xience Xpedition approved in Japan
Abbott (ABT) announced today that Xience Xpedition, a next generation DES (drug eluting stent), was approved by Ministry of Health, Labor and Welfare (MHLW) for the treatment of coronary artery disease (CAD), the most common form of heart disease, in Japan. Abbott noted that the Xience Xpedition's enhanced deliverability, combined with the broadest size matrix in the Japanese market that includes a unique 3.25 mm diameter for more accurate vessel sizing, will help physicians in Japan address a wide range of patients with CAD. We highlight that Xience Xpedition has already been launched in US, EU and other EM countries.

Japan DES market and Nobori sales
Japan DES market is approximately USD 500M as of 4Q12. Of four leaders, Medtronic (MDT) indicated 20% market share by 4Q12 with USD 30M sales in 4Q12, while Abbott previously expected market share recovery to 50% with the launch of Xience Xpedition. For Boston Scientific (BSX), the company mentioned share gains in Japanese market with the launch of PROMUS Element but did not quantify market share during 4Q12 earning call. In addition, Terumo management indicated that Nobori is likely to maintain 20% market share in 2013. However, we found quantification of the market share by different manufacturers is slightly different. We estimate Nobori has 16- 17% market share with JPY 1.9B sales run rate by 1Q13.

Reduce PT to SGD1.15
We reduce PT to SGD 1.15, based on 7X FY2014 EPS of USD 0.064, plus expected cash of USD 0.434 per share. This translates into an effective P/E multiple of 14X. We slightly reduce our FY2014 EPS to USD 0.064 from 0.066. The revised EPS represents no earnings growth for FY2014. We continue to anticipate stock volatility ahead as Biosensors is likely to miss consensus in the following quarters.



Source/Extract/Excerpts/来源/转贴/摘录: Deutsche Ba
Publish date:11/07/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock